Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products

References

• Littlewood RA, Vanable PA. Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care. AIDS Care. 2008;20(8):1002–1018.
   PubMed Web of Science ®Google Scholar
• Littlewood RA, Vanable PA. The relationship between CAM use and adherence to antiretroviral therapies among persons living with HIV. Health Psychol. 2014;33(7):660–667.
   PubMed Web of Science ®Google Scholar
• Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011;17(18):2288–2301.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. HIV Surveillance Report, 2014; vol. 26. [cited 2016 Jun 16]. Published November 2015. Available from: http://www.cdc.gov/hiv/library/reports/surveillance/.
   Google Scholar
• Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6(8):e17502.
   PubMed Web of Science ®Google Scholar
• Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, et al. All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41(2):433–445.
   PubMed Web of Science ®Google Scholar
• Qato DM, Wilder J, Schumm LP, et al. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–482.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; cited 2016 Jun 8; [Drug Interactions L-1]. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Alam C, Whyte-Allman SK, Omeragic A, et al. Role and modulation of drug transporters in HIV-1 therapy. Adv Drug Deliv Rev. 2016;103:121–143.
   PubMed Web of Science ®Google Scholar
• Nathan B, Bayley J, Waters L, et al. Cobicistat: a novel pharmacoenhancer for co-formulation with HIV protease and integrase inhibitors. Infect Dis Ther. 2013;2:111–122.
   PubMedGoogle Scholar
• Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755–1758.
   PubMed Web of Science ®Google Scholar
• Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016;125:63–70.
   PubMed Web of Science ®Google Scholar
• Descovy® [package insert]. Foster City (CA): Gilead Sciences, Inc.; 2016 Apr.
   Google Scholar
• Littlewood RA, Vanable PA. A global perspective on complementary and alternative medicine use among people living with HIV/AIDS in the era of antiretroviral treatment. Curr HIV/AIDS Rep. 2011;8(4):257–268.
   PubMedGoogle Scholar
• Mogatle S, Skinner M, Mills E, et al. Effect of African potato (Hypoxis hemerocallidea) on the pharmacokinetics of efavirenz. S Afr Med J. 2008;98(12):945–949.
   PubMed Web of Science ®Google Scholar
• Gwaza L, Aweeka F, Greenblatt R, et al. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis. 2013;17(10):e857–e861.
   PubMed Web of Science ®Google Scholar
• Kasibhatta R, Naidu MU. Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. Drugs R D. 2007;8(6):383–391.
   PubMedGoogle Scholar
• Molto J, Valle M, Miranda C, et al. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother. 2011;55(1):326–330.
   PubMed Web of Science ®Google Scholar
• Molto J, Valle M, Miranda C, et al. Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients. Antimicrob Agents Chemother. 2012;56(10):5328–5331.
   PubMed Web of Science ®Google Scholar
• Penzak SR, Robertson SM, Hunt JD, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy. 2010;30(8):797–805.
   PubMed Web of Science ®Google Scholar
• Demarles D, Gillotin C, Bonaventure-Paci S, et al. Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice. Antimicrob Agents Chemother. 2002;46(5):1589–1590.
   PubMed Web of Science ®Google Scholar
• Penzak SR, Acosta EP, Turner M, et al. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol. 2002;42(10):1165–1170.
   PubMed Web of Science ®Google Scholar
• Shelton MJ, Wynn HE, Hewitt RG, et al. Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J Clin Pharmacol. 2001;41(4):435–442.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998;45(4):355–359.
   PubMed Web of Science ®Google Scholar
• Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2003;55(2):199–202.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002;34(2):234–238.
   PubMed Web of Science ®Google Scholar
• Robertson SM, Davey RT, Voell J, et al. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin. 2008;24(2):591–599.
   PubMed Web of Science ®Google Scholar
• Blonk M, Colbers A, Poirters A, et al. Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers. Antimicrob Agents Chemother. 2012;56(10):5070–5075.
   PubMed Web of Science ®Google Scholar
• Andrade AS, Hendrix C, Parsons TL, et al. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med. 2008;8:50.
   PubMed Web of Science ®Google Scholar
• Calderon MM, Chairez CL, Gordon LA, et al. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers. Pharmacotherapy. 2014;34(11):1151–1158.
   PubMed Web of Science ®Google Scholar
• Lee LS, Wise SD, Chan C, et al. Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. J Clin Pharmacol. 2008;48(5):599–609.
   PubMed Web of Science ®Google Scholar
• Sandhu RS, Prescilla RP, Simonelli TM, et al. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol. 2003;43(11):1283–1288.
   PubMed Web of Science ®Google Scholar
• Molto J, Valle M, Miranda C, et al. Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother. 2012;56(6):2837–2841.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy. 2002;22(5):551–556.
   PubMed Web of Science ®Google Scholar
• DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003;23(7):866–870.
   PubMed Web of Science ®Google Scholar
• Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol. 2005;61(1):1–7.
   PubMed Web of Science ®Google Scholar
• DiCenzo R, Frerichs V, Larppanichpoonphol P, et al. Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults. Pharmacotherapy. 2006;26(9):1255–1261.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet. 2000;355(9203):547–548.
   PubMed Web of Science ®Google Scholar
• Frye R, Kroboth P, Folan M, et al. Effect of DHEA on CYP3A-mediated metabolism of triazolam [abstract PI-182]. Clin Pharmacol Ther. 2000;67:109.
   Web of Science ®Google Scholar
• Henderson MC, Miranda CL, Stevens JF, et al. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica. 2000;30(3):235–251.
   PubMed Web of Science ®Google Scholar
• Mannering GJ, Shoeman JA, Deloria LB. Identification of the antibiotic hops component, colupulone, as an inducer of hepatic cytochrome P-4503A in the mouse. Drug Metab Dispos. 1992;20(2):142–147.
   PubMed Web of Science ®Google Scholar
• Teotico DG, Bischof JJ, Peng L, et al. Structural basis of human pregnane X receptor activation by the hops constituent colupulone. Mol Pharmacol. 2008;74(6):1512–1520.
   PubMed Web of Science ®Google Scholar
• Bharate JB, Batarseh YS, Wani A, et al. Synthesis and P-glycoprotein induction activity of colupulone analogs. Org Biomol Chem. 2015;13(19):5488–5496.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415–426.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Mol Nutr Food Res. 2008;52(7):755–763.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Hubbard MA, et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008;83(1):61–69.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Barone GW, et al. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2007;35(2):240–245.
   PubMed Web of Science ®Google Scholar
• Brown AC. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 3 of 6. Food Chem Toxicol. 2016. pii: S0278-6915(16)30221-6. doi:10.1016/j.fct.2016.07.001. [Epub ahead of print]
   Google Scholar
• Mu Y, Zhang J, Zhang S, et al. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther. 2006;316(3):1369–1377.
   PubMed Web of Science ®Google Scholar
• Tu JH, He YJ, Chen Y, et al. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010;66(8):805–810.
   PubMed Web of Science ®Google Scholar
• Tu JH, Hu DL, Dai LL, et al. Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Xenobiotica. 2010;40(6):393–399.
   PubMed Web of Science ®Google Scholar
• Hou YC, Lin SP, Chao PD. Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A. Food Chem. 2012;135(4):2307–2312.
   PubMed Web of Science ®Google Scholar
• PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Cartilage (Bovine and Shark). Bethesda, MD: National Cancer Institute. Updated 2015 Dec 11. [cited 2016 Jul 7]. Available from: http://www.cancer.gov/about-cancer/treatment/cam/patient/cartilage-pdq. [PMID: 26389175]
   Google Scholar
• VandenBrink BM, Foti RS, Rock DA, et al. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2012;40(1):47–53.
   PubMed Web of Science ®Google Scholar
• Ojewole JA. Antinociceptive, anti-inflammatory and antidiabetic properties of hypoxis hemerocallidea fisch. & C.A. Mey. (Hypoxidaceae) corm [‘African Potato’] aqueous extract in mice and rats. J Ethnopharmacol. 2006;103(1):126–134.
   PubMed Web of Science ®Google Scholar
• Mills E, Cooper C, Seely D, et al. African herbal medicines in the treatment of HIV: hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J. 2005;4:19.
   PubMed Web of Science ®Google Scholar
• Brown L, Heyneke O, Brown D, et al. Impact of traditional medicinal plant extracts on antiretroviral drug absorption. J Ethnopharmacol. 2008;119(3):588–592.
   PubMed Web of Science ®Google Scholar
• Mills E, Foster BC, Van Heeswijk R, et al. Impact of African herbal medicines on antiretroviral metabolism. AIDS. 2005;19(1):95–97.
   PubMed Web of Science ®Google Scholar
• Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin Drug Metab Toxicol. 2011;7(6):721–729.
   PubMed Web of Science ®Google Scholar
• Khajuria A, Zutshi U, Bedi KL. Permeability characteristics of piperine on oral absorption–an active alkaloid from peppers and a bioavailability enhancer. Indian J Exp Biol. 1998;36(1):46–50.
   PubMedGoogle Scholar
• Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine. 2002;9(3):224–231.
   PubMed Web of Science ®Google Scholar
• Bhardwaj RK, Glaeser H, Becquemont L, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;302(2):645–650.
   PubMed Web of Science ®Google Scholar
• Volak LP, Ghirmai S, Cashman JR, et al. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008;36(8):1594–1605.
   PubMed Web of Science ®Google Scholar
• Pattanaik S, Hota D, Prabhakar S, et al. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. Phytother Res. 2009;23(9):1281–1286.
   PubMed Web of Science ®Google Scholar
• Wang YM, Lin W, Chai SC, et al. Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. Toxicol Appl Pharmacol. 2013;272(1):96–107.
   PubMed Web of Science ®Google Scholar
• Sandoval M, Charbonnet RM, Okuhama NN, et al. Cat’s claw inhibits TNFalpha production and scavenges free radicals: role in cytoprotection. Free Radic Biol Med. 2000;29(1):71–78.
   PubMed Web of Science ®Google Scholar
• Erowele GI, Kalejaiye AO. Pharmacology and therapeutic uses of cat’s claw. Am J Health Syst Pharm. 2009;66(11):992–995.
   PubMed Web of Science ®Google Scholar
• Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 2000;7(4):273–282.
   PubMed Web of Science ®Google Scholar
• Lopez Galera RM, Ribera Pascuet E, Esteban Mur JI, et al. Interaction between cat’s claw and protease inhibitors, atazanavir, ritonavir and saquinavir. Eur J Clin Pharmacol. 2008;64(12):1235–1236.
   PubMed Web of Science ®Google Scholar
• Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10(1):66–86.
   PubMed Web of Science ®Google Scholar
• Barnes J, Anderson LA, Gibbons S, et al. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005;57(8):929–954.
   PubMed Web of Science ®Google Scholar
• Birt DF, Widrlechner MP, Lalone CA, et al. Echinacea in infection. Am J Clin Nutr. 2008;87(2):488S–492S.
   PubMed Web of Science ®Google Scholar
• Ladenheim D, Horn O, Werneke U, et al. Potential health risks of complementary alternative medicines in HIV patients. HIV Med. 2008;9(8):653–659.
   PubMed Web of Science ®Google Scholar
• Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89–100.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther. 2004;76(5):428–440.
   PubMed Web of Science ®Google Scholar
• Malhotra S, Bailey DG, Paine MF, et al. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14–23.
   PubMed Web of Science ®Google Scholar
• Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin. 2004;25(2):129–136.
   PubMed Web of Science ®Google Scholar
• Egashira K, Fukuda E, Onga T, et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation. 2003;75(7):1057.
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 1997;25(11):1228–1233.
   PubMed Web of Science ®Google Scholar
• Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99(10):2545–2553.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Suzuki K, Nakanishi T, et al. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci. 2011;100(9):3843–3853.
   PubMed Web of Science ®Google Scholar
• Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol. 2003;43(8):831–839.
   PubMed Web of Science ®Google Scholar
• Weber ND, Andersen DO, North JA, et al. In vitro virucidal effects of Allium sativum (garlic) extract and compounds. Planta Med. 1992;58(5):417–423.
   PubMed Web of Science ®Google Scholar
• Sasaki J, Kita T, Ishita K, et al. Antibacterial activity of garlic powder against Escherichia coli O-157. J Nutr Sci Vitaminol (Tokyo). 1999;45(6):785–790.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Riggs DR. The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am. 2000;27(1):157–162, xi.
   PubMed Web of Science ®Google Scholar
• Bica I, Tang AM, Skinner S, et al. Use of complementary and alternative therapies by patients with human immunodeficiency virus disease in the era of highly active antiretroviral therapy. J Altern Complement Med. 2003;9(1):65–76.
   PubMed Web of Science ®Google Scholar
• Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci. 2001;4(2):176–184.
   PubMed Web of Science ®Google Scholar
• Wu CC, Sheen LY, Chen HW, et al. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem. 2002;50(2):378–383.
   PubMed Web of Science ®Google Scholar
• Berginc K, Kristl A. The effect of garlic supplements and phytochemicals on the ADMET properties of drugs. Expert Opin Drug Metab Toxicol. 2012;8(3):295–310.
   PubMed Web of Science ®Google Scholar
• Duncan A, Mills J. An unusual case of HIV virologic failure during treatment with boosted atazanavir. AIDS. 2013;27(8):1361–1362.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Devane CL, Chavin KD, et al. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther. 2003;74(2):170–177.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005;22(6):525–539.
   PubMed Web of Science ®Google Scholar
• Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011;25(5):561–575.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang L, Bao Y, et al. A sensitive method for the detection and quantification of ginkgo flavonols from plasma. Rapid Commun Mass Spectrom. 2007;21(6):971–981.
   PubMed Web of Science ®Google Scholar
• Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs. 2005;65(9):1239–1282.
   PubMed Web of Science ®Google Scholar
• Satsu H, Hiura Y, Mochizuki K, et al. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem. 2008;56(13):5366–5373.
   PubMed Web of Science ®Google Scholar
• Mohamed ME, Frye RF. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med. 2011;77(4):311–321.
   PubMed Web of Science ®Google Scholar
• Wiegman DJ, Brinkman K, Franssen EJ. Interaction of Ginkgo biloba with efavirenz. AIDS. 2009;23(9):1184–1185.
   PubMed Web of Science ®Google Scholar
• Naccarato M, Yoong D, Gough K. A potential drug-herbal interaction between Ginkgo biloba and efavirenz. J Int Assoc Physicians AIDS Care (Chic). 2012;11(2):98–100.
   PubMedGoogle Scholar
• Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phytomedicine- ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem. 2009;16(22):2924–2942.
   PubMed Web of Science ®Google Scholar
• Sung H, Kang SM, Lee MS, et al. Korean red ginseng slows depletion of CD4 T cells in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 2005;12(4):497–501.
   PubMedGoogle Scholar
• Sung H, Jung YS, Cho YK. Beneficial effects of a combination of Korean red ginseng and highly active antiretroviral therapy in human immunodeficiency virus type 1-infected patients. Clin Vaccine Immunol. 2009;16(8):1127–1131.
   PubMed Web of Science ®Google Scholar
• Cho M, Ye X, Dobs A, et al. Prevalence of complementary and alternative medicine use among HIV patients for perceived lipodystrophy. J Altern Complement Med. 2006;12(5):475–482.
   PubMed Web of Science ®Google Scholar
• Patel J, Buddha B, Dey S, et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther. 2004;11(4):262–277.
   PubMedGoogle Scholar
• Henderson GL, Harkey MR, Gershwin ME, et al. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 1999;65(15):PL209–PL214.
   PubMed Web of Science ®Google Scholar
• Malati CY, Robertson SM, Hunt JD, et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol. 2012;52(6):932–939.
   PubMed Web of Science ®Google Scholar
• He N, Edeki TI. Effects of ginseng components on c-DNA-expressed CYP3A4 mediated testosterone 6beta-hydroxylation in human liver microsomes [abstract]. Clin Pharmacol Ther. 2001;73:50.
   Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72(3):276–287.
   PubMed Web of Science ®Google Scholar
• Mateo-Carrasco H, Galvez-Contreras MC, Fernandez-Gines FD, et al. Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review. Drug Metabol Drug Interact. 2012;27(3):171–175.
   PubMedGoogle Scholar
• Rehman J, Dillow JM, Carter SM, et al. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett. 1999;68(2–3):391–395.
   PubMed Web of Science ®Google Scholar
• Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005;12(6):559–567.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135(5):1561–1567.
   PubMed Web of Science ®Google Scholar
• Payer BA, Reiberger T, Rutter K, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol. 2010;49(2):131–133.
   PubMed Web of Science ®Google Scholar
• Sridar C, Goosen TC, Kent UM, et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004;32(6):587–594.
   PubMed Web of Science ®Google Scholar
• Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003;304(3):1258–1267.
   PubMed Web of Science ®Google Scholar
• Gurley B, Hubbard MA, Williams DK, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006;46(2):201–213.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Barone GW, Williams DK, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006;34(1):69–74.
   PubMed Web of Science ®Google Scholar
• Harwood M, Danielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007;45(11):2179–2205.
   PubMed Web of Science ®Google Scholar
• Miles SL, McFarland M, Niles RM. Molecular and physiological actions of quercetin: need for clinical trials to assess its benefits in human disease. Nutr Rev. 2014;72(11):720–734.
   PubMed Web of Science ®Google Scholar
• Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2–3):325–337.
   PubMed Web of Science ®Google Scholar
• Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol. 1994;34(6):459–464.
   PubMed Web of Science ®Google Scholar
• Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000;294(1):88–95.
   PubMed Web of Science ®Google Scholar
• Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm. 2004;57(2):313–318.
   PubMed Web of Science ®Google Scholar
• Choi JS, Choi BC, Choi KE. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm. 2004;61(22):2406–2409.
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Kim HK, et al. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J Clin Pharmacol. 2005;45(8):941–946.
   PubMed Web of Science ®Google Scholar
• Di Carlo G, Borrelli F, Ernst E, et al. St John’s wort: prozac from the plant kingdom. Trends Pharmacol Sci. 2001;22(6):292–297.
   PubMed Web of Science ®Google Scholar
• Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf. 2004;27(11):773–797.
   PubMed Web of Science ®Google Scholar
• Moore LB, Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA. 2000;97(13):7500–7502.
   PubMed Web of Science ®Google Scholar
• De Maat MM, Hoetelmans RM, Math T RA, et al. Drug interaction between St John’s wort and nevirapine. AIDS. 2001;15(3):420–421.
   PubMed Web of Science ®Google Scholar
• Hafner V, Jager M, Matthee AK, et al. Effect of simultaneous induction and inhibition of CYP3A by St John’s Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther. 2010;87(2):191–196.
   PubMed Web of Science ®Google Scholar
• Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011;66(7):1567–1572.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64(1):45–50.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010;54(12):4999–5003.
   PubMed Web of Science ®Google Scholar
• Isentress® [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2014.
   Google Scholar
• Agarwala S. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects [abstract 11]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City, Canada.
   Google Scholar
• Agarwala S, Eley T, Villegas C, et al. Effect of famotidine 20 and 40 mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subject [Abstract 11]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City Canada.
   Google Scholar
• Wang X, Boffito M, Zhang J, et al. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. AIDS Patient Care STDS. 2011;25(9):509–515.
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Hoetelmans RM, Kestens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV negative volunteers. The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2007 Jul 22–25; Sydney, Australia.
   Google Scholar
• Agarwala S, Gray K, Eley T, et al. Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects [poster WePe3.3C08]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24–27; Rio de Janiero, Brazil.
   Google Scholar
• Agarwala S, Gray K, Wang Y, et al. Pharmacokinetic effect of omeprazole on atazanavir with ritonavir in healthy subjects [abstract 658]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston, MA.
   Google Scholar
• Reyataz® [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2015 Sept.
   Google Scholar
• Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489–492.
   PubMed Web of Science ®Google Scholar
• Crauwels HM, van Heeswijk RPG, Kestens D, et al. The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). The 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9–13; Glasgow, UK.
   Google Scholar
• Song I, Borland J, Arya N, et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55(5):490–496.
   PubMed Web of Science ®Google Scholar
• Slain D, Amsden JR, Khakoo RA, et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy. 2005;25(2):165–170.
   PubMed Web of Science ®Google Scholar
• Stribild® [package insert]. Foster City (CA): Gilead Sciences, Inc; 2016 Feb.
   Google Scholar
• Tivicay® [package insert]. Research Triangle Park (NC): ViiV Healthcare Company; 2016 Jun.
   Google Scholar
• Kiser JJ, Lichtenstein KA, Anderson PL, et al. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26(4):511–514.
   PubMed Web of Science ®Google Scholar
• Evotaz® [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2015 Jan.
   Google Scholar
• Akutsu T, Kobayashi K, Sakurada K, et al. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007;35(1):72–78.
   PubMed Web of Science ®Google Scholar
• The American Geriatrics Society Beers Criteria Update Expert Panel. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.
   PubMed Web of Science ®Google Scholar
• Saberi P, Phengrasamy T, Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med. 2013;14(9):519–529.
   PubMed Web of Science ®Google Scholar
• Norvir® [package insert]. North Chicago (IL): AbbVie, Inc; 2015 Nov.
   Google Scholar
• Tybost® [package insert]. Foster City (CA): Gilead Sciences, Inc; 2016 Jun.
   Google Scholar
• Flovent® [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2014.
   Google Scholar
• Boyd SD, Hadigan C, McManus M, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acquir Immune Defic Syndr. 2013;63(3):355–361.
   PubMed Web of Science ®Google Scholar
• Carten ML, Kiser JJ, Kwara A, et al. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol. 2012;2012:137192.
   PubMedGoogle Scholar
• U.S. Food & Drug Administration. FDA drug safety communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. 2016 Jun 10; [cited 2016 Jun 18]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm504617.htm
   Google Scholar
• Tayrouz Y, Ganssmann B, Ding R, et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther. 2001;70(5):405–414.
   PubMed Web of Science ®Google Scholar
• Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother. 2005;49(12):4903–4910.
   PubMed Web of Science ®Google Scholar
• Mathias AA, Germa P, Lee M, et al. GS-9350: a pharmacoenhancer without anti-HIV activity. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal, Canada.
   Google Scholar
• Sato PH, Zannoni VG. Stimulation of drug metabolism by ascorbic acid in weanling guinea-pigs. Biochem Pharmacol. 1974;23(22):3121–3128.
   PubMed Web of Science ®Google Scholar
• Mori T, Itoh S, Ohgiya S, et al. Regulation of CYP1A and CYP3A mRNAs by ascorbic acid in guinea pigs. Arch Biochem Biophys. 1997;348(2):268–277.
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Cooper CL, Foster BC, et al. Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity. Pharmacotherapy. 2005;25(12):1725–1728.
   PubMed Web of Science ®Google Scholar
• Fan J, Liu S, Du Y, et al. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J Pharmacol Exp Ther. 2009;330(2):389–402.
   PubMed Web of Science ®Google Scholar
• Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther. 2009;85(2):198–203.
   PubMed Web of Science ®Google Scholar
• Landes N, Pfluger P, Kluth D, et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol. 2003;65(2):269–273.
   PubMed Web of Science ®Google Scholar